Multi-Agent Secondary Chemoprevention of Oral Squamous Cell Carcinoma (OSCC)

Five-year survival rates for human papillomavirus-negative OSCCs have only marginally improved over the past 40 years and still hover around 50% [1]. Current management for patients following OSCC resection entails close clinical follow up supplemented with imaging (CT, PET or MRI). Recently, agents such as the VEGFR1 tyrosine kinase inhibitor bevacizumab were developed to exploit cancers' reliance on overexpressed pathways while reducing toxicities. Tumor-targeted treatments may provide initial benefits, however, signaling redundancies and compensatory mechanisms eventually reduce efficacy.